Intra-Cellular Therapies, Inc. (ITCI)

Intra-Cellular Therapies Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	513.93	464.37	250.31	83.8	22.81	0.06
Revenue Growth (YoY)	65.45%	85.51%	198.69%	267.35%	37537.14%	-
Cost of Revenue	36.89	33.75	20.44	8.04	1.9	0
Gross Profit	477.04	430.63	229.87	75.77	20.92	0.06
Selling, General & Admin	424.03	409.86	358.78	272.61	186.36	64.95
Research & Development	184.95	180.14	134.72	88.85	65.78	89.12
Operating Expenses	608.98	590.01	493.5	361.46	252.15	154.07
Operating Income	-131.94	-159.38	-263.63	-285.69	-231.23	-154.01
Other Expense / Income	-22.06	-20.34	-7.38	-1.57	-4.24	-6.29
Pretax Income	-109.88	-139.04	-256.25	-284.12	-226.99	-147.72
Income Tax	0.99	0.64	0.01	0.01	0.01	0
Net Income	-110.87	-139.67	-256.26	-284.13	-227.01	-147.72
Shares Outstanding (Basic)	97	96	94	81	70	55
Shares Outstanding (Diluted)	97	96	94	81	70	55
Shares Change	1.83%	1.95%	15.74%	15.47%	27.50%	0.87%
EPS (Basic)	-1.16	-1.46	-2.72	-3.50	-3.23	-2.68
EPS (Diluted)	-1.16	-1.46	-2.72	-3.50	-3.23	-2.68
Free Cash Flow	-98.52	-124.47	-270.96	-259.87	-230.34	-128.68
Free Cash Flow Per Share	-1.02	-1.30	-2.88	-3.20	-3.27	-2.33
Gross Margin	92.82%	92.73%	91.83%	90.41%	91.69%	100.00%
Operating Margin	-25.67%	-34.32%	-105.32%	-340.90%	-1013.58%	-254090.46%
Profit Margin	-21.57%	-30.08%	-102.37%	-339.04%	-995.07%	-243713.69%
Free Cash Flow Margin	-19.17%	-26.80%	-108.25%	-310.10%	-1009.69%	-212303.69%
EBITDA	-109.36	-138.51	-255.59	-283.59	-226.46	-147.24
EBITDA Margin	-21.28%	-29.83%	-102.11%	-338.40%	-992.70%	-242923.89%
Depreciation & Amortization	0.53	0.53	0.66	0.53	0.53	0.48
EBIT	-109.88	-139.04	-256.25	-284.12	-226.99	-147.72
EBIT Margin	-21.38%	-29.94%	-102.37%	-339.03%	-995.01%	-243711.05%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).